IRL-201104 is under clinical development by Revolo Biotherapeutics and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition ...

Telacebec is under clinical development by Qurient and currently in Phase II for Buruli Ulcer. According to GlobalData, Phase II drugs for Buruli Ulcer does not have sufficient historical data to ...

Eight months after the onset of symptoms, Mycobacterium tuberculosis was found in samples from mediastinal ... sourcing and editing of clinical images, investigation results, drawing original diagrams ...

One rare complication of TB is vasculitis, involving inflammation of the blood vessels by Mycobacterium tuberculosis. TB vasculitis typically ... sourcing and editing the clinical images, ...

Mycobacterium tuberculosis, the causative agent of tuberculosis, produces toxins and their antidotes to regulate its growth ...

Tuberculosis (TB) is the world’s biggest infectious disease killer with multidrug-resistant TB (MDR-TB) posing a particular ...

The Asansol division of Eastern Railway has embarked on a comprehensive 100 Days TB Elimination campaign, starting from 7 ...

The diagnosis of TBM and miliary TB was finally confirmed by positive CSF and sputum culture of Mycobacterium tuberculosis. The patient had a good response to standard antituberculous therapy ...

Prevention of drug-resistant tuberculosis is a global health priority. However, trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among contacts of persons with ...

Geelong recorded its worst year on record for several dangerous diseases, including a concerningly high number of “crypto” ...

Worldwide, approximately 2 million children younger than 15 years of age are infected with multidrug-resistant (MDR) Mycobacterium tuberculosis, with MDR tuberculosis developing in approximately ...

In the battle against tuberculosis, a global scourge that claims over 1.5 million lives annually, researchers are looking to ...